Clovis Oncology Inc (CLVS)

76.95
NASDAQ : Health Care
Prev Close 76.95
Day Low/High 0.00 / 0.00
52 Wk Low/High 25.50 / 99.45
Avg Volume 1.64M
Exchange NASDAQ
Shares Outstanding 48.88M
Market Cap 3.67B
EPS -9.10
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Clovis Oncology Presents Comprehensive Dataset From Successful Phase 3 ARIEL3 Maintenance Treatment Trial Of Rucaparib In Advanced Ovarian Cancer At ESMO 2017

Clovis Oncology Presents Comprehensive Dataset From Successful Phase 3 ARIEL3 Maintenance Treatment Trial Of Rucaparib In Advanced Ovarian Cancer At ESMO 2017

Clovis Oncology, Inc. (NASDAQ: CLVS) announced the first presentation of a comprehensive dataset from its Phase 3 ARIEL3 study of rucaparib at the 2017 European Society for Medical Oncology (ESMO) Congress taking place in...

Juno, bluebird In Focus as Targets Following Gilead-Kite Aquisition

Juno, bluebird In Focus as Targets Following Gilead-Kite Aquisition

More Immunotherapy Buyouts Likely After Kite Sale

Clovis Oncology To Present Comprehensive Dataset From Successful ARIEL3 Clinical Trial Program At 2017 ESMO Congress

Clovis Oncology To Present Comprehensive Dataset From Successful ARIEL3 Clinical Trial Program At 2017 ESMO Congress

Clovis Oncology, Inc. (NASDAQ: CLVS) today announced that abstracts highlighting progress in the rucaparib clinical development program will be presented at the 2017 European Society for Medical Oncology (ESMO) Congress...

One of Wall Street's Hottest Biotech Stocks Tanks, Is Now the Time to Pounce?

One of Wall Street's Hottest Biotech Stocks Tanks, Is Now the Time to Pounce?

One of the hottest biotech stocks of the last month is selling off.

Clovis Oncology Announces Second Quarter 2017 Operating Results

Clovis Oncology Announces Second Quarter 2017 Operating Results

Clovis Oncology, Inc. (NASDAQ:CLVS) reported financial results for the quarter ended June 30, 2017, and provided an update on the Company's clinical development programs and regulatory outlook for the remainder of...

Clovis Sell-Off May Be Overdone

Clovis Sell-Off May Be Overdone

Clovis Oncology, Intercept Pharmaceuticals and Editas Medicine were among the biotech premarket movers on July 31.

Discovery, Clovis, Hertz Are Monday's Worst Performing Stocks -- Here's Why

Discovery, Clovis, Hertz Are Monday's Worst Performing Stocks -- Here's Why

Several stocks spent Monday's trading session in the red, and here's why.

Clovis Oncology To Announce Second Quarter 2017 Financial Results And Host Webcast Conference Call On August 2

Clovis Oncology To Announce Second Quarter 2017 Financial Results And Host Webcast Conference Call On August 2

Clovis Oncology, Inc. (NASDAQ: CLVS) will announce its second quarter 2017 financial results on Wednesday, August 2, 2017, after the close of the U.

Clovis Oncology Announces Exercise In Full Of Underwriters' Option To Purchase Additional Shares Of Common Stock

Clovis Oncology, Inc. (NASDAQ:CLVS) announced today that the underwriters of its recently announced public offering of its common stock have exercised in full their option to purchase an additional 511,363 shares.

Clovis Oncology Announces Upsizing And Pricing Of Public Offering Of Common Stock

Clovis Oncology, Inc. (NASDAQ:CLVS) announced today the pricing of an underwritten public offering of 3,409,091 shares of its common stock at $88.

Biotech Movers: AveXis, Clovis, Epizyme

Biotech Movers: AveXis, Clovis, Epizyme

AveXis, Clovis Oncology and Epizyme were among the biotech stock movers in premarket trading on June 20.

Clovis Oncology Announces Proposed Offering Of Common Stock

Clovis Oncology, Inc. (NASDAQ:CLVS) announced today that it has commenced an underwritten public offering of shares of its common stock to raise aggregate proceeds of approximately $250 million.

Biotech Movers: Clovis, Seattle Genetics, Rigel

Biotech Movers: Clovis, Seattle Genetics, Rigel

Clovis Oncology, Seattle Genetics and Rigel Pharmaceuticals were among the biotech stock movers in premarket trading on June 19.

Clovis Oncology's Rucaparib Significantly Improved Progression-Free Survival In All Ovarian Cancer Patient Populations Studied In Phase 3 ARIEL3 Maintenance Treatment Trial

Clovis Oncology, Inc. (NASDAQ: CLVS) today announced topline data from the confirmatory phase 3 ARIEL3 trial of rucaparib, which successfully achieved the primary endpoint of improved progression-free survival (PFS) by...

Biotech Movers: Acceleron, Clovis, Coherus

Biotech Movers: Acceleron, Clovis, Coherus

Acceleron Pharma, Clovis Oncology and Coherus BioSciences premarket trading on Tuesday.

Clovis Oncology Announces Presentations At 2017 ASCO Annual Meeting

Clovis Oncology, Inc. (NASDAQ: CLVS) today announced that abstracts highlighting progress in the rucaparib clinical development program will be presented at the 2017 American Society of Clinical Oncology (ASCO) Annual...

Analysts' Actions -- AMD, Clovis, ConocoPhillips, Disney, Transocean and More

Analysts' Actions -- AMD, Clovis, ConocoPhillips, Disney, Transocean and More

Here are Wednesday's top research calls, including new coverage of Advanced Micro Devices and Transocean, upgrades for Clovis Oncology and ConocoPhillips, and a downgrade for Disney.

Biotech Stock Mailbag: Why Clovis Oncology Is Trading Lower on Rubraca Study Update

Biotech Stock Mailbag: Why Clovis Oncology Is Trading Lower on Rubraca Study Update

Some investors are disappointed with the timing of Clovis' ovarian cancer maintenance clinical trial.

Clovis Oncology Announces First Quarter 2017 Operating Results

Clovis Oncology, Inc. (NASDAQ:CLVS) reported financial results for the quarter ended March 31, 2017, and provided an update on the Company's clinical development programs and regulatory outlook for the remainder of...

Clovis Oncology To Announce First Quarter 2017 Financial Results And Host Webcast Conference Call On May 3

Clovis Oncology, Inc. (NASDAQ: CLVS) will announce its first quarter 2017 financial results on Wednesday, May 3, 2017, after the close of the U.

Tesaro Resorts to PR Razzle Dazzle to Make Ovarian Cancer Drug Appear Cheaply Priced

Tesaro Resorts to PR Razzle Dazzle to Make Ovarian Cancer Drug Appear Cheaply Priced

Tesaro's newly approved PARP inhibitor Zejula is really 50% more expensive than its list price implies.

Shortened FDA Advisory Panel Is Bad Omen for Puma Bio's Controversial Breast Cancer Drug

Shortened FDA Advisory Panel Is Bad Omen for Puma Bio's Controversial Breast Cancer Drug

Over the past five years, the FDA has often used half-day sessions of the Oncologic Drugs Advisory Committee (ODAC) to administer public floggings to flawed cancer drugs.

These Stocks Show a Change of Direction

These Stocks Show a Change of Direction

Finding bullish and bearish reversals in the market.

Clovis Oncology Announces Data Presentations At AACR Annual Meeting 2017

Clovis Oncology, Inc. (NASDAQ: CLVS) today announced that rucaparib preclinical data will be presented at the American Association for Cancer Research (AACR) Annual Meeting 2017.

Tesaro Secures Early and Broad Approval for PARP Inhibitor in Ovarian Cancer

Tesaro Secures Early and Broad Approval for PARP Inhibitor in Ovarian Cancer

The new Tesaro ovarian cancer drug will be marketed under the brand name Zejula.

Look for Clovis Oncology to Resume Its Advance

Look for Clovis Oncology to Resume Its Advance

More gains await patient CLVS holders.

Notable Wednesday Option Activity: CLVS, KMG, NYLD

Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in Clovis Oncology Inc , where a total volume of 7,551 contracts has been traded thus far today, a contract volume which is representative of approximately 755,100 underlying shares (given that every 1 contract represents 100 underlying shares). That number works out to 42.5% of CLVS's average daily trading volume over the past month, of 1.8 million shares.